TV-301
Alzheimer's disease (prodromal to mild)
Key Facts
About TheraVac Biologics
TheraVac Biologics is a preclinical-stage biotech leveraging a proprietary VLP platform to develop active immunotherapies for neurodegenerative and chronic inflammatory diseases. Founded in 2016 and based in San Diego, the company's pipeline is led by TV-301 for Alzheimer's disease and TV-202 for frontotemporal dementia, both in preclinical development. The platform aims to generate strong, targeted immune responses without traditional adjuvants, potentially offering safer and more effective treatments for conditions with high unmet medical need. The company is privately held and appears to be pre-revenue, advancing its programs through academic collaborations.
View full company profileAbout TheraVac Biologics
TheraVac Biologics is a preclinical-stage biotech leveraging a proprietary VLP platform to develop active immunotherapies for neurodegenerative and chronic inflammatory diseases. Founded in 2016 and based in San Diego, the company's pipeline is led by TV-301 for Alzheimer's disease and TV-202 for frontotemporal dementia, both in preclinical development. The platform aims to generate strong, targeted immune responses without traditional adjuvants, potentially offering safer and more effective treatments for conditions with high unmet medical need. The company is privately held and appears to be pre-revenue, advancing its programs through academic collaborations.
View full company profile